Wednesday, 8 July 2015

Roche gets boost as multiple sclerosis drug works in big trials

Source Reuters:

A drug being developed by Roche to treat multiple sclerosis (MS) met main and secondary objectives in two studies, boosting the company's hopes of expanding beyond its core cancer franchise.

The studies of MS treatment ocrelizumab showed the drug, which is injected, slows relapses and the progression of the disabilities that come with the disease when compared with Rebif, an established injectable drug, the company said on Tuesday.  Read on